

Supporting Information

Yashiro-Ohtani et al. 10.1073/pnas.1407079111




Fig. S1. Notch1 signaling regulates H3K27 acetylation of the murine *Myc* 3' enhancer element (NDME). (A) T6E T-ALL cells treated with DMSO or 1 μ M compound E for 16 h, or with compound E for 16 h followed by GSI washout and 4 h of additional incubation, were fixed and analyzed by local ChIP assay. ChIPs in *Left* were prepared with antibody specific for histone H3 acetylated at K27, whereas those in *Right* were prepared with a nonspecific Ig, as described (1). Data were obtained in triplicate in independent experiments; error bars correspond to the SEM. (B) Notch specifically regulates NDME activity. T6E cells were transfected with *Renilla* luciferase control (pRLTK), *Myc* promoter construct (*MycPro*) or the murine *Myc* enhancer reporter construct (*MycProNDME*) and either empty vector or a vector driving expression of the dominant-negative form of mastermind-like1 (DN-MAML).

1. Wang H, et al. (2014) NOTCH1-RBPJ complexes drive target gene expression through dynamic interactions with superenhancers. *Proc Natl Acad Sci USA* 111(2):705–710.

Myc 3' enhancer alignment

```

mouse AAAGCTACTCTTAGAGGCAATTTGACAGAGCTGTCCTTTGAAACTGGCATTCTTAAGTG 60
human AAAGTGTTCTTAGTGGCAATTTAACAGAGCTGTCCTTTGAAAGTGGCATTCTTAAGTA 60
      **** *  ***** ***** ***** ***** ***** ***** ***** *****

mouse TTCTTCTAAATTACAGTTGGGCCATAAATATGGCAGGTTAAACGGAGACAGCTGAGAAAAT 120
human TTCTCCTAAATTGCAGTTGGGCCATAAATACAACAGGTTAAACTAAGGCAGCTGGGAAAAT 120
      **** ***** ***** ***** ***** ***** ***** ***** *****

mouse GGTGTAGGTGAAAAATTACAAGGATGGGATCTTTCTCCTCTCCACATGAAGATTTAATC 180
human TATATAGGTGAAAAATTACAAGGACAGATCTTCCACTCAAGCATGTAAGATTTAATC 180
      * ***** ***** ***** * ***** * * * *****

                                     RBPJ site B
mouse TGCCAGATTAATAAACCCCTGAACCTGGTGATTGTGTCAGATAACAGCTTGGAGGATGCT 240
human TCCCAGGTTAAAAA-CCCAGAACACAGTGAATTAAGTGTGAGATAACAGCTCAGAGGATGCT 239
      * **** ***** * * * * * ***** * ***** ***** *****

                                     RBPJ site A
mouse CAGAGATGGGGTCCAGGTTT-CAAGGGAT-GGGTCTGTGGCCTACAGAGGCAGGT 298
human CAGAGATGGGGTCCCATGGTATTTCTGGGACCGGGTCTGTGCCTGCAGAGGCAGGT 299
      ***** ***** * * * * * * * * * ***** ***** ***** *****

mouse GTTCTCAGTTGG-AGCACAGAGGAGTTCTTGGCACCAGCACTGGGCCAGCTGTGAGTTT 357
human GTTCCCAGTGGGGAGCACAGAGGAGCCCTTTCACCCGTATCAGGCCAGCTGTGAGTTT 359
      ***** * * * ***** * * * * * * * * * ***** ***** *

mouse ATCTGTGGTATCTGGCTTTCAAAGTAGTGTTCCTGCAGTCTGCCTAAAAGAAAGAGATG 417
human ATCTGTGGCATCTCGCTTTCAGGAACGGTTCCCCAGGTCTGCCTAGGAGAAAG----- 414
      ***** * * * ***** * * ***** ***** ***** *****

mouse ATCAAGATGAACGAAGAGGTAATTGCACTGTACTCTACTCTGATGGGAAAAAGGGGGAG 477
human -TT--GATGAACCACATGGGAAGTGTACAGCATATTA-----ACAGGAAAAAATGTAAA 466
      * ***** * * * * * * * * * * * * * * * ***** * *

mouse AATTATGAAAGAAAAATATATAT 500
human AATCATGAAACA----- 478
      *** ***** *
  
```

Fig. S2. Sequence alignment of murine and human NDME elements.




Fig. S3. Short-term Notch inhibition does not affect the interaction of the human *Myc* 3' enhancer element (NDME) with the *Myc* promoter. Human CUTLL1 cells treated for 3 d with DMSO or 1 μ M compound E were fixed and analyzed by 3C assay. The "probe" primer was located at the *Myc* promoter. Positions of other primers are shown in Fig. 5C. The 3C quantitative PCR (qPCR) products were quantified relative to the amounts of products generated with the same primer pairs, using a DNA substrate consisting of HindIII-digested, randomly ligated BAC DNA encompassing this region of the human genome. Data were obtained in triplicate in independent experiments; error bars correspond to the SEM.




Fig. S4. Quantification of the effects of acute and chronic changes in Notch activation on chromatin landscapes in the Myc 3' superenhancer region. (A) Scatterplot of H3K27ac ChIP-Seq read counts. Each dot represents an H3K27ac peak identified in CUTLL1 cells following GSI washout. CHIP-Seq reads within 600 bp of a peak summit were counted in the Notch-on and -off states. Red dots indicate peaks with dynamic Notch1 binding sites (described in ref. 1), and blue dots indicate peaks without dynamic Notch1 binding sites. (B) Chromatin landscapes in human CUTLL1 cells for Notch1, H3K27ac, and Brd4 are shown in the Notch-on state. (C) Genomic location of labeled peaks in A. (D) Quantification of changes in H3K27Ac peaks in CUTLL1 cells after 3 d of GSI treatment and 4 h after Notch1 reactivation by GSI washout (expressed as W4h/GSI) and in Notch-dependent (GSI naïve) and Notch-independent (GSI resistant) DND-41 and KOPTK-1 cells (expressed as GSI naïve/resistant). (E) Quantification of changes in Brd4 peaks in Notch-dependent (GSI naïve) and Notch-independent (GSI resistant) DND-41 and KOPTK-1 cells (expressed as GSI naïve/resistant).

1. Wang H, et al. (2014) NOTCH1-RBPJ complexes drive target gene expression through dynamic interactions with superenhancers. *Proc Natl Acad Sci USA* 111(2):705–710.




Fig. S5. Notch1 signaling regulates H3K27 acetylation of the human NDME and BDME. (A) Position of primers used to perform H3K27ac local ChIP superimposed over Notch1 and H3K27ac ChIP-Seq data obtained from human CUTLL1 and KOPT-K1 T-ALL cells. (B and C) NDME c1 and NDME c2 denote two regions in peak c, and BDME h1 and BDME h2 denote two regions in peak h that were amplified using specific primer pairs. CUTLL1 and KOPT-K1 T-ALL cells treated with vehicle (DMSO) or 1 μ M compound E (GSI) for 3 d were fixed and analyzed by local ChIP assays prepared with nonspecific IgG or antibody specific for K27-acetylated histone H3. Data were obtained in triplicate; error bars correspond to SD. *P* values were determined with Student *t* test.

Table S1. Primers used in these studies

	Forward	Reverse
ChIP primers		
Mouse Hes1 promoter	5'-TGCAGCGTCTCTGGGTTGTA-3'	5'-CCAGGACCAAGGAGAGAGGT-3'
Mouse Dtx1 intron3	5'-CGTGTCTCTTCCCTCCATTG-3'	5'-CCTGAGAGGAAGCGGTGT-3'
Mouse Myc enhancer	5'-ACCCTGAACCTGGTGATTGTG-3'	5'-CCACAGACCCATCCCTTGAA-3'
Mouse Nanog	5'-GGCTGCCTCTCCCTCGCCCT-3'	5'-GTGCACACAGCTGGGCCTGA-3'
Human NDME c1	5'-GAGGCCCCATTATTACCC-3'	5'-CCAGGTAGGGGATTACGTC-3'
Human NDME c2	5'-GCTGCCACATGCTGATGAAC-3'	5'-GCAGTTCTTCTACGCTGGT-3'
Human BDME h1	5'-AGGAGCCCACCTTCTCATTT-3'	5'-ACATTGCAAGAGTGGCTGTG-3'
Human BDME h2	5'-AGGAAGTGGCTTTCACATGC-3'	5'-GCGTGCAAAAGAGAGAAACC-3'
human neg cont (+1M of MYC)	5'-AATGCTGGGCTTCCAAGGA-3'	5'-GACCTTGGTGACTGTTGAGGAAAC-3'
Cloning primers for pGL3		
Mouse Myc promoter	5'-GGTACCACGGTTTTCTTTATTCTAGGGTCT-3'	5'-GCTAGCCCCCAATAGACAAAAATCCCT-3'
Mouse Myc enhancer	5'-GGATCCACTGTTTGATTCTACCTCCCAA-3'	5'-GGATCCTAGGCAGACTGCAGGGAAC-3'
Human MYC enhancer	5'-GGTACCGCTGTCCTTTGAAAGTGGCATT-3'	5'-GGTACCGCTGTACAGTTCCCATGTGGT-3'
Primers for 3C		
Mouse		
Myc probe	5'-FAM/AAGCCCTGCCCTTCAGGAGGC/TAMRA-3'	
Myc promoter F	5'-GTCCGACTCGCCTCACTCA-3'	
Myc control	5'-CCGCTCACFCCCTCTGTCTC-3'	
Myc promoter R	5'-CAAGGTTAGTGCCAAAGTCCATCT-3'	
Myc +224 K	5'-TGGTCTCCGGTGCGAGTTTG-3'	
Myc +746 K	5'-CAGCATGAATTATTGACTTCTTGAAT-3'	
Human		
MYC probe	5'-FAM/CCCAGAAATGCTGGCTTTGCCA/TAMRA-3'	
MYC promoter F	5'-CTGCTACCTACCTCCAAGCCTTA-3'	
MYC control R	5'-CCGCTCACFCCCTCTGTCTC-3'	
MYC promoter R	5'-GAGTGCATTCTCTCCACCACAGT-3'	
NDME -80K	5'-TCTCCAGAATGCTGTAAGTAGACCA-3'	
NDME -60K	5'-GAATTCTATGTGCTCAGTGCCCTAAC-3'	
NDME -30K	5'-CTCCATTCCCTTCTGTATCTGCTATT-3'	
Mouse		
Myc+1M R	5'-AAGGCTCCAGGTCAATGTG-3'	
NDME -30K	5'-TGTTTGCTTGCTTGCTTGATT-3'	
NDME -20K	5'-CAAAGGCAGGATGGTTACTTTAGAA-3'	
NDME	5'-GTGTGTCACCGTGATTGTTCACT-3'	
NDME +40K	5'-TAAGGTAGACTTTCATCTGACACAAA-3'	
Human		
NDME	5'-CTCCAGAGACAACAAGAGTGAGAAGAA-3'	
NDME +30K	5'-CAGCATTATCCATAGTAGCTCCAAACT-3'	
BDE E2 -23K	5'-ACCCATAAGCACAGGCAAC-3'	
BDE E2	5'-GGTTCCAAAATCCGAGCTGA-3'	
BDE E3	5'-GCATGGCAGTGGTCACAGTT-3'	
BDE E4	5'-AAGAAGGTGGTTCTACCAAGAAAGG-3'	
BDE E4 +25K	5'-CCTGAAACCTGATTGCTCATGTAA-3'	
Myc+1M R	5'-AAGGCTCCAGGTCAATGTG-3'	